|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Impairment charges | |||||
| Casualty loss, net | |||||
| Casualty (gain) loss, net | |||||
| Casualty gain | |||||
| Depreciation and amortization | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other (expense) income, net | |||||
| Interest and other expense | |||||
| Interest and other income | |||||
| Interest income, net | |||||
| Unrealized Loss on Fair Value Remeasurement, fair value | |||||
| Total interest and other (expense) income, net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Preferred stock dividends | |||||
| Warrants, deemed dividend | |||||
| Induced conversion of warrants | |||||
| Warrant modification | |||||
| Net loss attributable to common stockholders | |||||
| Net loss attributable to common stockholders per share: | |||||
| Basic and diluted net loss per share (in dollars per share) | |||||
| Diluted net loss per share (in dollars per share) | |||||
| Weighted-average number of shares of common stock: | |||||
| Basic and diluted (in shares) | |||||
| Diluted (in shares) | |||||
Loading...